PMID- 22314025
OWN - NLM
STAT- MEDLINE
DCOM- 20121217
LR  - 20220408
IS  - 1478-6362 (Electronic)
IS  - 1478-6354 (Print)
IS  - 1478-6354 (Linking)
VI  - 14
IP  - 1
DP  - 2012 Feb 7
TI  - Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still 
      independently predictive of radiographic progression in a longitudinal 
      observational cohort at 8 years follow up.
PG  - R30
LID - 10.1186/ar3734 [doi]
AB  - INTRODUCTION: At present, there is no reliable tool for predicting disease 
      outcome in patients with rheumatoid arthritis (RA). We previously demonstrated an 
      association between specific baseline biomarkers/clinical measures including 
      matrix metalloproteinase-3 (MMP-3) and 2-year radiographic progression in 
      patients with RA. This study further evaluates the predictive capability of these 
      baseline variables with outcome extended over 8-years. METHODS: Fifty-eight of 
      the original cohort (n = 118) had radiographic progression from baseline to mean 
      8.2-years determined using the van der Heijde modified Sharp method. The 
      contribution of each predictor variable towards radiographic progression was 
      assessed with univariate and multivariate analyses. RESULTS: Traditional factors 
      (including erythrocyte sedimentation rate, C-reactive protein, anti-cyclic 
      citrullinated peptide (anti-CCP), and rheumatoid factor) and biomarkers of tissue 
      destruction (including MMP-3, C-telopeptide of type II collagen, cartilage 
      oligomeric matrix protein, and tissue inhibitor of metalloproteinase 1) measured 
      at baseline were associated with radiographic progression at endpoint. 
      Multivariate logistic regression identified anti-CCP seropositivity [OR 9.29, 
      95%CI: 2.29-37.64], baseline elevated MMP-3 [OR 8.25, 95%CI: 2.54-26.78] and 
      baseline radiographic damage [OR 5.83, 95%CI: 1.88-18.10] as the strongest 
      independent predictors of radiographic progression. A model incorporating these 
      variables had a predictive accuracy of 0.87, assessed using the area under the 
      receiver operating characteristic curve. CONCLUSION: In our cohort with onset of 
      RA symptoms < 2-years, multivariate analysis identified anti-CCP status and 
      baseline MMP-3 as the strongest independent predictors of radiographic disease 
      outcome at 8.2-years. This finding suggests determination of baseline MMP-3, in 
      conjunction with traditional serologic markers, may provide additional prognostic 
      information for patients with RA. Furthermore, these findings highlight the 
      importance of continued research into a broad range of biomarkers as potential 
      predictors of joint damage.
FAU - Houseman, Mark
AU  - Houseman M
AD  - Institute of Cellular Medicine, Musculoskeletal Research Group, Newcastle 
      University, 4th Floor Catherine Cookson Building, The Medical School, Framlington 
      Place, Newcastle upon Tyne, NE2 4HH, UK.
FAU - Potter, Catherine
AU  - Potter C
FAU - Marshall, Nicola
AU  - Marshall N
FAU - Lakey, Rachel
AU  - Lakey R
FAU - Cawston, Tim
AU  - Cawston T
FAU - Griffiths, Ian
AU  - Griffiths I
FAU - Young-Min, Steven
AU  - Young-Min S
FAU - Isaacs, John D
AU  - Isaacs JD
LA  - eng
GR  - G1001518/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120207
PL  - England
TA  - Arthritis Res Ther
JT  - Arthritis research & therapy
JID - 101154438
RN  - 0 (Biomarkers)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*blood/*diagnosis/diagnostic imaging
MH  - Biomarkers/*blood
MH  - Disease Progression
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Logistic Models
MH  - Longitudinal Studies
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Observation
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Radiography
MH  - Time Factors
PMC - PMC3392825
EDAT- 2012/02/09 06:00
MHDA- 2012/12/18 06:00
PMCR- 2012/02/07
CRDT- 2012/02/09 06:00
PHST- 2011/09/16 00:00 [received]
PHST- 2012/01/09 00:00 [revised]
PHST- 2012/02/07 00:00 [accepted]
PHST- 2012/02/09 06:00 [entrez]
PHST- 2012/02/09 06:00 [pubmed]
PHST- 2012/12/18 06:00 [medline]
PHST- 2012/02/07 00:00 [pmc-release]
AID - ar3734 [pii]
AID - 10.1186/ar3734 [doi]
PST - epublish
SO  - Arthritis Res Ther. 2012 Feb 7;14(1):R30. doi: 10.1186/ar3734.